On February 4, 2026, Express Scripts agreed to a settlement with the Federal Trade Commission (FTC) in the agency’s administrative case against the nation’s three largest pharmacy benefit managers ...
The Federal Trade Commission has reached a landmark settlement with Express Scripts, addressing allegations of inflated drug prices and rebate-driven formulary exclusions. The agreement bans the PBM ...
On February 4, 2026, the Federal Trade Commission (FTC) proposed to settle its enforcement action against leading pharmacy benefit manager (PBM) Express Scripts, going beyond the insulin products that ...
The MarketWatch News Department was not involved in the creation of this content. Settlement resolves FTC lawsuit alleging that Express Scripts' conduct resulted in artificially inflated insulin drug ...
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is ...
Regulatory shake-up: FTC settlements, DOL proposals, and CAA 2026 reforms are redefining PBM compensation, transparency, and rebate pass-through requirements. Pricing policy clash: Federal anti-rebate ...
The Seventh Amendment entitles litigants to a jury trial unless the claim would have been heard, and the remedy awarded, by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results